Memantine Monotherapy for Executive Dysfunction and ADHD
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a 12-week clinical trial evaluating the efficacy and safety of memantine
hydrochloride (Memantine HC1, brand name Namenda) in the treatment of executive function
deficits (EFDs) in adults with Attention Deficit Hyperactivity Disorder (ADHD). After
screening procedures, memantine is prescribed in randomized, double-blind fashion (equal
chance of medication or placebo) for 12 weeks.
The investigators hypothesize that memantine hydrochloride will prove to be an effective,
safe, and well-tolerated agent for the treatment of EFDs in individuals with ADHD interested
in non-stimulant medications.